These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 6530763)

  • 1. [Therapy of systemic lupus erythematosus--studies using disease models. 1. The effect of MHC on lupus nephritis in (NZB x NZW)F1--a therapeutic suggestion].
    Sato H; Hirose S; Shirai S
    Nihon Rinsho; 1984 Dec; 42(12):2791-5. PubMed ID: 6530763
    [No Abstract]   [Full Text] [Related]  

  • 2. Analysis of the New Zealand Black contribution to lupus-like renal disease. Multiple genes that operate in a threshold manner.
    Drake CG; Rozzo SJ; Hirschfeld HF; Smarnworawong NP; Palmer E; Kotzin BL
    J Immunol; 1995 Mar; 154(5):2441-7. PubMed ID: 7868910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estrogen receptor-alpha deficiency attenuates autoimmune disease in (NZB x NZW)F1 mice.
    Bynoté KK; Hackenberg JM; Korach KS; Lubahn DB; Lane PH; Gould KA
    Genes Immun; 2008 Mar; 9(2):137-52. PubMed ID: 18200028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in expression of lupus nephritis in New Zealand mixed H-2z homozygous inbred strains of mice derived from New Zealand black and New Zealand white mice. Origins and initial characterization.
    Rudofsky UH; Evans BD; Balaban SL; Mottironi VD; Gabrielsen AE
    Lab Invest; 1993 Apr; 68(4):419-26. PubMed ID: 8479150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic studies on the skin lupus band test in New Zealand mice.
    Furukawa F; Maruyama N; Yoshida H; Hamashima Y; Hirose S; Shirai T
    Clin Exp Immunol; 1985 Jan; 59(1):146-52. PubMed ID: 3871675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with high doses of anti-IgM prevents, but with lower doses accelerates autoimmune disease in (NZW x BXSB)F1 hybrid mice.
    Cerny A; Starobinski M; Hügin AW; Sutter S; Zinkernagel RM; Izui S
    J Immunol; 1987 Jun; 138(12):4222-8. PubMed ID: 3495583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Therapy of systemic lupus erythematosus--studies using disease models. 2. Suppression of anti-ds DNA antibody formation in NZB/W mice and improvement of glomerulonephritis].
    Okuhira H; Terada E; Fukuda K; Ogita T; Miyamoto A
    Nihon Rinsho; 1984 Dec; 42(12):2795-800. PubMed ID: 6530764
    [No Abstract]   [Full Text] [Related]  

  • 8. IL-4Ralpha polymorphism in regulation of IL-4 synthesis by T cells: implication in susceptibility to a subset of murine lupus.
    Shiroiwa W; Tsukamoto K; Ohtsuji M; Lin Q; Ida A; Kodera S; Ohtsuji N; Nakamura K; Tsurui H; Kinoshita K; Nishimura H; Shirai T; Hirose S
    Int Immunol; 2007 Feb; 19(2):175-83. PubMed ID: 17189592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic analysis of the imperfect association of H-2 haplotype with lupus-like autoimmune disease.
    Babcock SK; Appel VB; Schiff M; Palmer E; Kotzin BL
    Proc Natl Acad Sci U S A; 1989 Oct; 86(19):7552-5. PubMed ID: 2571993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Self-reactive T cells in murine lupus: analysis of genetic contributions and development of self-tolerance.
    Kotzin BL; Herron LR; Babcock SK; Portanova JP; Palmer E
    Clin Immunol Immunopathol; 1989 Nov; 53(2 Pt 2):S35-46. PubMed ID: 2571438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contribution of the gene linked to the T cell receptor beta chain gene complex of NZW mice to the autoimmunity of (NZB x NZW)F1 mice.
    Hirose S; Tokushige K; Kinoshita K; Nozawa S; Saito J; Nishimura H; Shirai T
    Eur J Immunol; 1991 Mar; 21(3):823-6. PubMed ID: 1826267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Contribution of murine models of spontaneous lupus to the analysis of genetic factors in human disease].
    Tron F
    Ann Med Interne (Paris); 1990; 141(3):217-21. PubMed ID: 2195946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Control of separate pathogenic autoantibody responses marks MHC gene contributions to murine lupus.
    Vyse TJ; Halterman RK; Rozzo SJ; Izui S; Kotzin BL
    Proc Natl Acad Sci U S A; 1999 Jul; 96(14):8098-103. PubMed ID: 10393954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hidden anti-nuclear antibodies in sero-negative systemic lupus erythematosus patients and in NZB and (NZB x NZW) F 1 mice.
    Blomjous FJ; Feltkamp-Vroom TM
    Eur J Immunol; 1971 Nov; 1(5):396-8. PubMed ID: 4110262
    [No Abstract]   [Full Text] [Related]  

  • 15. Analysis of MHC class II genes in the susceptibility to lupus in New Zealand mice.
    Rozzo SJ; Vyse TJ; David CS; Palmer E; Izui S; Kotzin BL
    J Immunol; 1999 Mar; 162(5):2623-30. PubMed ID: 10072504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic contributions to lupus-like disease in NZB/NZW mice.
    Kotzin BL; Palmer E
    Am J Med; 1988 Dec; 85(6A):29-31. PubMed ID: 3264457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic control of the spontaneous activation of CD4+ Th cells in systemic lupus erythematosus-prone (NZB x NZW) F1 mice.
    Fujii T; Iida Y; Yomogida M; Ikeda K; Haga T; Jikumaru Y; Ninami M; Nishimura N; Kodera Y; Inada Y; Shirai T; Hirose S; Nishimura H
    Genes Immun; 2006 Dec; 7(8):647-54. PubMed ID: 17024131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Y chromosome from autoimmune BXSB/MpJ mice induces a lupus-like syndrome in (NZW x C57BL/6)F1 male mice, but not in C57BL/6 male mice.
    Izui S; Higaki M; Morrow D; Merino R
    Eur J Immunol; 1988 Jun; 18(6):911-5. PubMed ID: 3260184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic administration of interleukin-4 expressing plasmid DNA delays the development of glomerulonephritis and prolongs survival in lupus-prone female NZB x NZW F1 mice.
    Hayashi T; Hasegawa K; Sasaki Y; Mori T; Adachi C; Maeda K
    Nephrol Dial Transplant; 2007 Nov; 22(11):3131-8. PubMed ID: 17670770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of lupus-prone NZB/NZW F1 mice with recombinant soluble Fc gamma receptor II (CD32).
    Werwitzke S; Trick D; Sondermann P; Kamino K; Schlegelberger B; Kniesch K; Tiede A; Jacob U; Schmidt RE; Witte T
    Ann Rheum Dis; 2008 Feb; 67(2):154-61. PubMed ID: 17557887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.